Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims anchored to the labeled indications and pharmacology are largely supported; however critical safety-related content (contraindications, boxed warnings, pregnancy/pediatric safety, dosing/administration, monitoring, and related warnings) is omitted, leading to partial alignment.
Category Scores
Accurate Statements
Mounjaro is a brand-name prescription medication used to improve glycemic control in adults with type 2 diabetes.
1 INDICATIONS AND USAGE
Its active ingredient is tirzepatide.
11 DESCRIPTION
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
12.1 Mechanism of Action
Tirzepatide mimics the actions of GIP and GLP-1, two incretin hormones that help regulate blood sugar.
12.1 Mechanism of Action
By activating these receptors, tirzepatide can lower blood glucose levels and improve glycemic control.
12.2 Pharmacodynamics; 1 INDICATIONS AND USAGE
Unsupported Statements
Information regarding Mounjaro's patent expiration specifically in India is not publicly available through the provided sources.
Not present in the provided FDA labeling sections.
Patent timelines can vary significantly by country due to differing patent laws and application processes.
Not present in the provided FDA labeling sections.
Mounjaro received its initial approval from the FDA on May 13, 2022.
Not present in the FDA labeling sections.
In many countries, including the United States, new drugs are eligible for a period of patent protection, typically 20 years from the filing date of the patent application.
Not present in the FDA labeling sections.
However, this period can be extended through patent term extensions to compensate for regulatory review time.
Not present in the FDA labeling sections.
Consulting resources like DrugPatentWatch.com can be beneficial for patent information.
Not present in the FDA labeling sections.
These platforms track patent filings, grants, and expiry timelines globally.
Not present in the FDA labeling sections.
Once a drug's patent expires, generic manufacturers can produce and market their own versions.
Not present in the FDA labeling sections.
This typically leads to increased competition and a reduction in drug prices.
Not present in the FDA labeling sections.
For diabetes medications, patent expiration can impact cost and availability of tirzepatide-containing treatments.
Not present in the FDA labeling sections.
Mounjaro is manufactured by Eli Lilly and Company.
Not present in the FDA labeling sections.
Other medications in this GLP-1 class, such as semaglutide (Ozempic, Wegovy), are used for diabetes and weight management.
Not present in the FDA labeling sections.
These drugs have different mechanisms and may have different patent and exclusivity timelines.
Not present in the FDA labeling sections.
Contradictions
Important Omissions
Contraindications
Importance:
High
Boxed warnings
Importance:
High
8.1 Pregnancy
Importance:
High
8.4 Pediatric Use
Importance:
High
2 Dosing and Administration
Importance:
High
Warnings and Precautions
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Overall alignment is limited by omissions of safety-related label elements; identified statements align with label content in mechanism, indication, and pharmacodynamics but critical safety sections are not addressed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Missing safety labeling elements (contraindications, boxed warnings, pregnancy, pediatric use, dosing/administration, warnings and precautions) and related monitoring information.
Suggested Improvement
Incorporate complete safety labeling coverage including contraindications; boxed warnings (if applicable); pregnancy and pediatric use; dosing and administration details; warnings and precautions; monitoring recommendations; adverse reactions; drug interactions; and storage/handling where relevant.